GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (CHIX:IDIAz) » Definitions » COGS-to-Revenue

Idorsia (CHIX:IDIAZ) COGS-to-Revenue : 0.04 (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Idorsia COGS-to-Revenue?

Idorsia's Cost of Goods Sold for the three months ended in Mar. 2025 was CHF2.4 Mil. Its Revenue for the three months ended in Mar. 2025 was CHF58.9 Mil.

Idorsia's COGS to Revenue for the three months ended in Mar. 2025 was 0.04.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Idorsia's Gross Margin % for the three months ended in Mar. 2025 was 95.85%.


Idorsia COGS-to-Revenue Historical Data

The historical data trend for Idorsia's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Idorsia COGS-to-Revenue Chart

Idorsia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only - - 0.06 0.05 0.32

Idorsia Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.05 0.45 0.33 0.04

Idorsia COGS-to-Revenue Calculation

Idorsia's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=35.926 / 112.508
=0.32

Idorsia's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2.441 / 58.883
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Idorsia  (CHIX:IDIAz) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Idorsia's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 2.441 / 58.883
=95.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Idorsia COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Idorsia's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Idorsia Business Description

Traded in Other Exchanges
Address
Hegenheimermattweg 91, Allschwil, CHE, 4123
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide innovative therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.

Idorsia Headlines

No Headlines